If we analyse the results displayed in Table 2, the presence of a KRAS mutation in ctDNA is observed in nearly 70–80% of locally advanced and metastatic patients while this value ranges from 30% to 68% for patients with resectable tumours. Here, KRAS is linked to neoplasm.